Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

GermanyBack to Germany

Clinical trials in Ulm – page 31

574 clinical trials in Ulm, Germany across 2 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

GermanyOur site in GermanyKlinischeStudien.de(opens in a new tab)
Ulm at a glance
574
clinical trials
  • Research sites2
Type of trial
Recruitment status
Quick filters

574 trials in Ulm

Open in trial search

Colorectal cancer metastatic+2

Not recruiting

Study on Methadone Hydrochloride and Drug Combination for Patients with Advanced Metastatic Colorectal Cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Fluorouracil
  • Sponsor:AIO-Studien gGmbH

Breast cancer+4

Not recruiting

Study of Pembrolizumab and Olaparib for Patients with Advanced HER2 Negative Breast Cancer and Specific Genetic Mutations

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Olaparib
  • Sponsor:Institut fuer Frauengesundheit GmbH

Pancreatic carcinoma metastatic

Not recruiting

Study of RMC-6236 compared to standard therapy in previously treated metastatic pancreatic ductal adenocarcinoma

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Fluorouracil
  • Sponsor:Revolution Medicines Inc.

Pancreatic carcinoma

Not recruiting

Study on Quemliclustat and Chemotherapy for Patients with Metastatic Pancreatic Cancer

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Gemcitabine
  • Sponsor:Arcus Biosciences Inc.

Multiple sclerosis

Not recruiting

Study on Frexalimab for Adults with Nonrelapsing Secondary Progressive Multiple Sclerosis

Investigational
Countries:GermanyGermany
  • Participants:18–64 years
  • Substances:Frexalimab
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Colitis ulcerative

Not recruiting

Study on the Effects of Zasocitinib for Patients with Moderate to Severe Ulcerative Colitis

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Zasocitinib
  • Sponsor:Takeda Development Center Americas Inc.

Breast cancer+1

Not recruiting

Study of PF-07220060 and Fulvestrant for Adults with Advanced or Metastatic HR-positive, HER2-negative Breast Cancer After Previous Treatment

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Everolimus
  • Sponsor:Pfizer Inc.

Primary progressive multiple sclerosis

Not recruiting

Study on Tolebrutinib for Patients with Primary Progressive Multiple Sclerosis

Investigational
Countries:GermanyGermany
  • Participants:18–64 years
  • Substances:Tolebrutinib
  • Sponsor:Genzyme Corp.

Crohn's disease

Not recruiting

Study on BI 706321 and Ustekinumab for Patients with Moderate to Severe Crohn's Disease

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Bi 706321
  • Sponsor:Boehringer Ingelheim International GmbH

Relapsing multiple sclerosis

Not recruiting

Study on Fenebrutinib and Teriflunomide for Adults with Relapsing Multiple Sclerosis

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years
  • Substances:Fenebrutinib
  • Sponsor:F. Hoffmann-La Roche AG

Acute graft versus host disease in intestine

Not recruiting

Study on MaaT013 for Treating Acute Gastrointestinal Graft-Versus-Host Disease in Patients Not Responding to Ruxolitinib

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Allogeneic Faecal Microbiota, Pooled
  • Sponsor:Maat Pharma

Acute myeloid leukaemia

Not recruiting

Study on the Safety and Effectiveness of Ivosidenib or Enasidenib with Azacitidine for Patients with Newly Diagnosed Acute Myeloid Leukemia with IDH1 or IDH2 Mutations

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Azacitidine
  • Sponsor:Celgene Corp.

Other cities in Germany

The busiest research cities in the country

All 516 cities in Germany

Clinical research in Ulm

What the registry says about research in the country

01 Oncology Research

Groundbreaking trials focusing on colorectal cancer, acute myeloid leukemia, and various types of lymphomas. Studies are evaluating novel combination therapies and targeted treatments for patients with specific genetic mutations.

  • Metastatic Colorectal Cancer Treatment
  • B-Cell Lymphoma Therapies
  • Advanced Breast Cancer Studies

Multiple trials investigating innovative treatment approaches for blood cancers and solid tumors.

02 Neurological Disorders

Clinical research targeting multiple sclerosis, Alzheimer's disease, and amyotrophic lateral sclerosis. Studies are exploring new therapeutic agents and diagnostic tools.

  • Early-Stage Alzheimer's Treatment
  • Progressive MS Therapies
  • ALS Gene-Targeted Treatments

Innovative approaches in neurodegenerative disease management and treatment.

03 Autoimmune Conditions

Comprehensive studies on inflammatory bowel diseases, rheumatoid arthritis, and Sjögren's disease. Research focuses on novel biological therapies and long-term treatment options.

  • Crohn's Disease Treatments
  • Ulcerative Colitis Management
  • Autoimmune Disorder Therapies

Advanced therapeutic approaches for chronic inflammatory conditions.

Back to GermanyAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.